Amrita Vishwa Vidyapeetham announced on Thursday that it has got approval from the Central Drugs Standard Control Organization (CDSCO) for conducting a pilot clinical trial for a novel bone graft developed jointly by Amrita School of Nanosciences, Amrita School of Medicine, and Amrita School of Dentistry, Kochi.
The synthetic bone graft, named Nanotex Bone, provides a first-of-its-kind solution in the world for patients who lose part of their lower jaw (mandibular bone) due to cancer, injury, or trauma. The product, patented by Amrita Vishwa Vidyapeetham, can enable patients to lead a close-to-normal life even after losing a portion of their oral cavity bone, according to the doctors.
On the possibility of whether the recipient’s body may reject the graft, Dr. Subramania Iyer, Professor & Chairman of Plastic & Reconstructive Surgery and Head & Neck Surgery at Amrita School of Medicine, Kochi told Financial Express.com: “The fibula flap is one standard which we use in all the patient and through a microsurgical method we have about 90-95 percent of survival rate. Our success rate is equivalent to the world’s rate. We do such surgeries quite frequently. So, that is not an issue. But putting this implant on that and looking at the survival that’s what we are looking at.